Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LDL Hypothesis Brings Out Skeptics, Supporters At FDA Panel

Executive Summary

Agency told advisory committee weighing the IMPROVE-IT data not to debate the LDL-hypothesis; panelists did so anyway.

You may also be interested in...



Keeping Track: FDA Approves Briviact, Refuses To File Firdapse, Rejects Remune

The latest drug development news and highlights from our FDA Performance Tracker.

FDA’s Zetia/Vytorin Rejection Leaves Cholesterol Drug Sponsors In Limbo

FDA’s complete response letter for the cardiovascular risk reduction claim for Zetia/Vytorin was expected, but what will this mean for sponsors of drugs with other mechanisms, like PCSK9?

Does Esperion's Plan For A Statin-Intolerant Claim Have A Shot?

Esperion says it is working with FDA to forge a new regulatory path for its cholesterol drug ETC-1002 in statin-intolerant patients – a population the agency has been very cautious about in the past.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel